Overview

Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults

Status:
COMPLETED
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetic drug-drug interactions, safety, and tolerability of co-administration of VX-993 and metformin in healthy participants.
Phase:
PHASE1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Metformin